$DVAX
DYNAVAX TECHNOLOGIES CORP

2014 Q4 Form 10-K Financial Statement

#000156459015001348 Filed on March 05, 2015

View on sec.gov

Income Statement

Concept 2014 Q4 2014 2013 Q4
Revenue $2.277M $11.03M $2.847M
YoY Change -20.02% -1.96% 57.64%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $5.050M $17.76M $3.710M
YoY Change 36.12% -33.9% -60.06%
% of Gross Profit
Research & Development $19.64M $84.58M $12.13M
YoY Change 61.91% 66.27% -3.12%
% of Gross Profit
Depreciation & Amortization $380.0K $1.400M $340.0K
YoY Change 11.76% 5.26% 9.68%
% of Gross Profit
Operating Expenses $24.69M $84.58M $15.84M
YoY Change 55.87% 66.27% -27.37%
Operating Profit -$91.31M
YoY Change 37.33%
Interest Expense -$10.00K $35.00K $40.00K
YoY Change -125.0% -70.83% -108.0%
% of Operating Profit
Other Income/Expense, Net $130.0K $433.0K -$100.0K
YoY Change -230.0% -224.43% 150.0%
Pretax Income -$22.29M -$91.12M -$13.06M
YoY Change 70.67% 35.99% -36.42%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$22.29M -$90.72M -$13.06M
YoY Change 70.7% 35.97% -36.45%
Net Earnings / Revenue -978.74% -822.5% -458.59%
Basic Earnings Per Share
Diluted Earnings Per Share -$847.9K -$3.451M -$552.9K
COMMON SHARES
Basic Shares Outstanding 262.6M
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q4 2014 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $122.7M $122.7M $189.4M
YoY Change -35.23% -35.22% 51.38%
Cash & Equivalents $49.51M $49.50M $23.12M
Short-Term Investments $73.14M $73.10M $166.3M
Other Short-Term Assets $4.100M $4.100M $1.400M
YoY Change 192.86% 192.86% -33.33%
Inventory
Prepaid Expenses
Receivables $700.0K $700.0K $1.627M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $127.4M $127.4M $192.4M
YoY Change -33.76% -33.78% 50.08%
LONG-TERM ASSETS
Property, Plant & Equipment $7.900M $7.900M $8.706M
YoY Change -9.26% -9.2% 9.3%
Goodwill $2.579M
YoY Change 4.2%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $700.0K $700.0K $297.0K
YoY Change 135.69% -30.0% -37.21%
Total Long-Term Assets $10.86M $10.90M $12.24M
YoY Change -11.28% -10.66% 5.87%
TOTAL ASSETS
Total Short-Term Assets $127.4M $127.4M $192.4M
Total Long-Term Assets $10.86M $10.90M $12.24M
Total Assets $138.3M $138.3M $204.6M
YoY Change -32.41% -32.4% 46.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.200M $1.200M $1.901M
YoY Change -36.88% -36.84% -12.23%
Accrued Expenses $6.317M $13.30M $5.764M
YoY Change 9.59% 62.2% -42.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $20.28M $20.30M $16.19M
YoY Change 25.24% 25.31% -14.84%
LONG-TERM LIABILITIES
Long-Term Debt $9.559M $9.600M $0.00
YoY Change
Other Long-Term Liabilities $1.070M $8.000M $963.0K
YoY Change 11.11% 280.95% 53.1%
Total Long-Term Liabilities $10.63M $17.60M $963.0K
YoY Change 1003.74% 738.1% 53.1%
TOTAL LIABILITIES
Total Short-Term Liabilities $20.28M $20.30M $16.19M
Total Long-Term Liabilities $10.63M $17.60M $963.0K
Total Liabilities $37.81M $37.80M $18.33M
YoY Change 106.29% 106.56% -26.47%
SHAREHOLDERS EQUITY
Retained Earnings -$502.2M
YoY Change 15.32%
Common Stock $695.1M $688.7M
YoY Change 0.93% 376213.11%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $100.5M $100.5M $186.3M
YoY Change
Total Liabilities & Shareholders Equity $138.3M $138.3M $204.6M
YoY Change -32.41% -32.4% 46.42%

Cashflow Statement

Concept 2014 Q4 2014 2013 Q4
OPERATING ACTIVITIES
Net Income -$22.29M -$90.72M -$13.06M
YoY Change 70.7% 35.97% -36.45%
Depreciation, Depletion And Amortization $380.0K $1.400M $340.0K
YoY Change 11.76% 5.26% 9.68%
Cash From Operating Activities -$16.87M -$73.74M -$11.84M
YoY Change 42.48% 25.68% 55.99%
INVESTING ACTIVITIES
Capital Expenditures -$460.0K $1.667M -$310.0K
YoY Change 48.39% 2.33% -74.17%
Acquisitions
YoY Change
Other Investing Activities $37.57M $92.26M -$102.3M
YoY Change -136.74% -285.56% -1865.98%
Cash From Investing Activities $37.11M $90.60M -$102.6M
YoY Change -136.18% -276.43% -2334.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 9.760M 9.900M 125.3M
YoY Change -92.21% -92.11% -983.57%
NET CHANGE
Cash From Operating Activities -16.87M -73.74M -11.84M
Cash From Investing Activities 37.11M 90.60M -102.6M
Cash From Financing Activities 9.760M 9.900M 125.3M
Net Change In Cash 30.00M 26.76M 10.88M
YoY Change 175.74% 74.04% -163.33%
FREE CASH FLOW
Cash From Operating Activities -$16.87M -$73.74M -$11.84M
Capital Expenditures -$460.0K $1.667M -$310.0K
Free Cash Flow -$16.41M -$75.41M -$11.53M
YoY Change 42.32% 25.05% 80.44%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
73141000
CY2013Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
166254000
CY2013Q4 dvax Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2402000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
6125000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1173000
CY2014Q4 us-gaap Long Term Debt
LongTermDebt
9559000
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
963000
CY2013Q4 us-gaap Liabilities
Liabilities
18328000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
263000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
688390000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-148000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-502211000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
186294000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
204622000
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
35000000
CY2014Q4 dvax Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
6938000
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5764000
CY2013 us-gaap Contracts Revenue
ContractsRevenue
4929000
CY2013 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
8469000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25943000
CY2014 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-90722000
CY2014Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
5865000
CY2014Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
6900000
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-69949000
CY2014 us-gaap Business Exit Costs1
BusinessExitCosts1
386000
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-75189000
CY2013 us-gaap Business Exit Costs1
BusinessExitCosts1
926000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
114826000
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-29819000
CY2014Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-24777000
CY2014Q2 us-gaap Net Income Loss
NetIncomeLoss
-24777000
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29819000
CY2014Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-22286000
CY2014Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
69500000
CY2014Q4 us-gaap Liabilities
Liabilities
37808000
CY2014Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
695058000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16192000
CY2014Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26307000
CY2014Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26307000
CY2014Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2014Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1070000
CY2014 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
84580000
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.10
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17047000
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
291000
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.83
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-66488000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-67596000
CY2014 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1404000
CY2014 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1553000
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
447000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-66273000
CY2014 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-92243000
CY2012 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
307000
CY2014 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
32000
CY2013 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
523000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
99880000
CY2014 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-3.45
CY2014 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-1521000
CY2014Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6317000
CY2014 us-gaap Operating Income Loss
OperatingIncomeLoss
-91311000
CY2014 us-gaap Investment Income Interest
InvestmentIncomeInterest
191000
CY2014Q4 us-gaap Liabilities Current
LiabilitiesCurrent
20279000
CY2012 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
48000
CY2012 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
366000
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19628000
CY2014 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26289000
CY2012 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-293000
CY2013 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-76000
CY2012 us-gaap Interest Expense
InterestExpense
2351000
CY2013 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-348000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
10439000
CY2014 us-gaap Net Income Loss
NetIncomeLoss
-90722000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-69949000
CY2012 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
414000
CY2014 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
433000
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-69535000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-66720000
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
116000
CY2014 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
17377000
CY2014 us-gaap Interest Expense
InterestExpense
35000
CY2013 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
224000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-70792000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
284000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
843000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-66720000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-69949000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2013 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-22678000
CY2012 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-23650000
CY2013 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-178000
CY2012 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
-89000
CY2013 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
2515000
CY2012 dvax Income Tax Reconciliation Deferred Compensation Charges
IncomeTaxReconciliationDeferredCompensationCharges
1002000
CY2012 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
21966000
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
22000000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-13840000
CY2013 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1327000
CY2012 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1207000
CY2014 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
24000
CY2013 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-18000
CY2012 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-8000
CY2014 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-881000
CY2013 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-923000
CY2012 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-1298000
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26280000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26280000
CY2012 us-gaap Contracts Revenue
ContractsRevenue
4610000
CY2014 us-gaap Costs And Expenses
CostsAndExpenses
102343000
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
77739000
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
77310000
CY2012 dvax Issuance Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Value
IssuanceOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsValue
1955000
CY2012 dvax Issuance Of Common Stock And Warrants Value
IssuanceOfCommonStockAndWarrantsValue
71780000
CY2013 dvax Issuance Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Value
IssuanceOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsValue
112000
CY2012 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
2190000
CY2014 us-gaap Provision For Lease Losses
ProvisionForLeaseLosses
386000
CY2013 us-gaap Provision For Lease Losses
ProvisionForLeaseLosses
926000
CY2014 us-gaap Share Based Compensation
ShareBasedCompensation
6089000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
12340000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
10439000
CY2014 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-900000
CY2013 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
622000
CY2012 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-8522000
CY2014 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
2683000
CY2013 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
80999000
CY2013 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
44209000
CY2013 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
-143000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12340000
CY2014 dvax Issuance Of Common Stock Upon Exercise Of Options Vesting Of Restricted Stock Units And Vesting Of Early Exercised Options Value
IssuanceOfCommonStockUponExerciseOfOptionsVestingOfRestrictedStockUnitsAndVestingOfEarlyExercisedOptionsValue
49000
CY2014 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
130000
CY2014 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
163000
CY2014 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6089000
CY2013 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
-677000
CY2012 us-gaap Increase Decrease In Other Current Assets
IncreaseDecreaseInOtherCurrentAssets
922000
CY2014 dvax Increase Decrease In Restricted Cash And Other Assets For Operating Activities
IncreaseDecreaseInRestrictedCashAndOtherAssetsForOperatingActivities
-277000
CY2013 dvax Increase Decrease In Restricted Cash And Other Assets For Operating Activities
IncreaseDecreaseInRestrictedCashAndOtherAssetsForOperatingActivities
-176000
CY2012 dvax Increase Decrease In Restricted Cash And Other Assets For Operating Activities
IncreaseDecreaseInRestrictedCashAndOtherAssetsForOperatingActivities
116000
CY2014 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-523000
CY2013 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-657000
CY2012 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
126000
CY2014 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
4810000
CY2013 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-2291000
CY2012 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
1916000
CY2014 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
5467000
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-4770000
CY2012 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1472000
CY2014 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-73738000
CY2013 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-58673000
CY2012 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-43809000
CY2014 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
44807000
CY2013 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
192044000
CY2012 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
206149000
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
16000
CY2013Q4 us-gaap Deferred Revenue
DeferredRevenue
2500000
CY2014 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
137071000
CY2014 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
9559000
CY2012 us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
15000000
CY2014 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
9901000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
125401000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
59042000
CY2014 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-371000
CY2013 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
147000
CY2012 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
118000
CY2014 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
26389000
CY2013 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
142321000
CY2012 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
169387000
CY2014 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1667000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1629000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2931000
CY2014 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
90597000
CY2013 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-51352000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-39693000
CY2013 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
80856000
CY2012 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
71780000
CY2013 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
44209000
CY2014 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
49000
CY2013 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
112000
CY2012 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1955000
CY2014 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
130000
CY2013 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
224000
CY2012 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
307000
CY2014 us-gaap Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
163000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
15523000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-24342000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7599000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31941000
CY2014 dvax Supplemental Disposal Of Assets
SupplementalDisposalOfAssets
841000
CY2013 dvax Supplemental Disposal Of Assets
SupplementalDisposalOfAssets
86000
CY2012 dvax Supplemental Disposal Of Assets
SupplementalDisposalOfAssets
169000
CY2014 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) requires management to make informed estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ materially from these estimates.</p></div>
CY2014 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentration of Credit Risk and Other Risks and Uncertainties </p> <p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">We operate in one business segment, which is the discovery and development of biopharmaceutical products. We determine our segments based on the way we organize our business by making operating decisions and assessing performance. In fiscal years 2014, 2013 and 2012, 96%, 89% and 88% of our revenues were earned in the United States, respectively, and the remaining revenues were earned in Germany. As of December&#160;31, 2014 and 2013, 11% and 9%, respectively, of our long-lived assets were located in the United States and the remaining long-lived assets were located in Germany.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that are subject to concentration of credit risk consist primarily of cash equivalents, marketable securities and accounts receivable. Our policy is to invest cash in institutional money market funds and marketable securities of U.S. government and corporate issuers with high credit quality to limit the amount of credit exposure. We currently maintain a portfolio of cash equivalents and marketable securities in a variety of securities, including short-term money market funds and U.S. government agency securities. We have not experienced any losses on our cash equivalents and marketable securities. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable are recorded at invoice value. We review our exposure to accounts receivable, including the requirement for allowances based on management&#8217;s judgment. We have not historically experienced any significant losses. We do not currently require collateral for any of our accounts receivable. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our products will require approval from the U.S. Food and Drug Administration (&#8220;FDA&#8221;) and foreign regulatory agencies before commercial sales can commence. There can be no assurance that our products will receive any of these required approvals. The denial or delay of such approvals would have a material adverse impact on our business. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are subject to risks common to companies in the biopharmaceutical industry, including, but not limited to, new technological innovations, clinical development risk, establishment of appropriate commercial partnerships, protection of proprietary technology, compliance with government and environmental regulations, uncertainty of market acceptance of products, product liability, the volatility of our stock price and the need to obtain additional financing.</p></div>
CY2014Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
122700000
CY2014 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2013 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2014 us-gaap Business Acquisition Effective Date Of Acquisition1
BusinessAcquisitionEffectiveDateOfAcquisition1
2006-04-30
CY2014 us-gaap Business Acquisition Description Of Acquired Entity
BusinessAcquisitionDescriptionOfAcquiredEntity
In April 2006, we completed the acquisition of Rhein Biotech GmbH (“Rhein” or “Dynavax Europe”), a wholly-owned subsidiary in Düsseldorf, Germany.
CY2014 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
ten-for-one
CY2014 dvax Reverse Stock Split Effective Date
ReverseStockSplitEffectiveDate
2014-11-07
CY2014 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2014Q4 us-gaap Fair Value Equity Level1 To Level2 Transfers Amount
FairValueEquityLevel1ToLevel2TransfersAmount
0
CY2014Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
122651000
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
189407000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
11000
CY2014Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
10000
CY2013Q4 us-gaap Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
47000
CY2014Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
122652000
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
189376000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
72390000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Amortized Cost
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsAmortizedCost
750000
CY2014Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
73140000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
72391000
CY2014Q4 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
750000
CY2014Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
73141000
CY2012 us-gaap Marketable Securities Realized Gain Loss
MarketableSecuritiesRealizedGainLoss
0
CY2014Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
8171000
CY2013Q4 us-gaap Machinery And Equipment Gross
MachineryAndEquipmentGross
8968000
CY2014Q4 dvax Laboratory Equipment Gross
LaboratoryEquipmentGross
6473000
CY2013Q4 dvax Laboratory Equipment Gross
LaboratoryEquipmentGross
7227000
CY2014Q4 dvax Computer Equipment Gross
ComputerEquipmentGross
2196000
CY2013Q4 dvax Computer Equipment Gross
ComputerEquipmentGross
1962000
CY2014Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
1070000
CY2013Q4 us-gaap Furniture And Fixtures Gross
FurnitureAndFixturesGross
1056000
CY2014Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
5690000
CY2013Q4 us-gaap Leasehold Improvements Gross
LeaseholdImprovementsGross
6048000
CY2014Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
935000
CY2013Q4 us-gaap Property Plant And Equipment Other
PropertyPlantAndEquipmentOther
762000
CY2014Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24535000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2264000
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
26023000
CY2014Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
16611000
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
17317000
CY2014Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
4613000
CY2013Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
3639000
CY2014Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
224000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
339000
CY2014Q4 dvax Accrued Third Party Research Expenses Current
AccruedThirdPartyResearchExpensesCurrent
5898000
CY2013Q4 dvax Accrued Third Party Research Expenses Current
AccruedThirdPartyResearchExpensesCurrent
900000
CY2014Q4 dvax Accrued Third Party Development Expenses Current
AccruedThirdPartyDevelopmentExpensesCurrent
1000000
CY2013Q4 dvax Accrued Third Party Development Expenses Current
AccruedThirdPartyDevelopmentExpensesCurrent
1313000
CY2014Q4 dvax Accrued Third Party Regulatory Expenses Current
AccruedThirdPartyRegulatoryExpensesCurrent
40000
CY2013Q4 dvax Accrued Third Party Regulatory Expenses Current
AccruedThirdPartyRegulatoryExpensesCurrent
189000
CY2014Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1480000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1786000
CY2014Q4 dvax Accrued Research And Development Expenses And Accrued Liabilities Current
AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent
13255000
CY2013Q4 dvax Accrued Research And Development Expenses And Accrued Liabilities Current
AccruedResearchAndDevelopmentExpensesAndAccruedLiabilitiesCurrent
8166000
CY2014 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1700000
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1900000
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1700000
CY2014Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
600000
CY2013Q4 us-gaap Deferred Rent Credit
DeferredRentCredit
600000
CY2014 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-700000
CY2013 us-gaap Gain Loss On Sale Of Leased Assets Net Operating Leases
GainLossOnSaleOfLeasedAssetsNetOperatingLeases
-700000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
2213000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2313000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1282000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
519000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
1687000
CY2014Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
10278000
CY2014 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
25500000
CY2014Q3 dvax Number Of Healthy Workers Placebo Was Delivered By Inhalation
NumberOfHealthyWorkersPlaceboWasDeliveredByInhalation
45
CY2014 dvax Description Of Doses Well Tolerated
DescriptionOfDosesWellTolerated
15.4 mg/week
CY2014Q1 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
5400000
CY2014Q4 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
8000000
CY2011 us-gaap Revenue Recognition Milestone Method Revenue Recognized
RevenueRecognitionMilestoneMethodRevenueRecognized
3000000
CY2014 us-gaap Deferred Revenue Revenue Recognized
DeferredRevenueRevenueRecognized
1100000
CY2014Q4 us-gaap Debt Instrument Interest Rate Effective Percentage
DebtInstrumentInterestRateEffectivePercentage
0.0975
CY2014 us-gaap Debt Instrument Interest Rate Terms
DebtInstrumentInterestRateTerms
The interest rate for each tranche in the Loan Agreement is calculated at a rate equal to the greater of either (i) 9.75% plus the prime rate as reported from time to time in The Wall Street Journal minus 5.25%, and (ii) 9.75%
CY2014 us-gaap Debt Instrument Payment Terms
DebtInstrumentPaymentTerms
Payments under the Loan Agreement are interest only until February 1, 2016 (which will be extended until August 1, 2016, if we achieve Milestone A on or before September 30, 2015, and which will be extended until February 1, 2017, if we meet certain additional HEPLISAV-B Phase 3 related milestones (“Milestone B”) on or before August 1, 2016). The interest only period will be followed by equal monthly payments of principal and interest amortized over a 30 month schedule through the scheduled maturity date on July 1, 2018 (which would be extended through January 1, 2019 if we achieve Milestone A on or before September 30, 2015 or Milestone B on or before August 1, 2016) (the “Loan Maturity Date”).
CY2014 us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2018-07-01
CY2014 dvax Debt Instrument Extension Date
DebtInstrumentExtensionDate
2019-01-01
CY2014 us-gaap Proceeds From Repayments Of Debt
ProceedsFromRepaymentsOfDebt
2400000
CY2014 dvax Advance Payment On Loan Agreement
AdvancePaymentOnLoanAgreement
40000000
CY2014 us-gaap Debt Issuance Costs
DebtIssuanceCosts
400000
CY2014Q4 us-gaap Long Term Debt And Capital Lease Obligations
LongTermDebtAndCapitalLeaseObligations
12343000
CY2014Q4 us-gaap Long Term Debt And Capital Lease Obligations Repayments Of Principal In Next Twelve Months
LongTermDebtAndCapitalLeaseObligationsRepaymentsOfPrincipalInNextTwelveMonths
929000
CY2014Q4 us-gaap Long Term Debt And Capital Lease Obligations Maturities Repayments Of Principal In Years Two And Three
LongTermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearsTwoAndThree
8753000
CY2014 us-gaap Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
-30818000
CY2014Q4 us-gaap Longterm Debt And Capital Lease Obligations Maturities Repayments Of Principal In Years Four And Five
LongtermDebtAndCapitalLeaseObligationsMaturitiesRepaymentsOfPrincipalInYearsFourAndFive
2661000
CY2014 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7422000
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7293000
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2827000
CY2014Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
43430
CY2008Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2008Q4 us-gaap Dividend Payable Date To Be Paid Day Month And Year
DividendPayableDateToBePaidDayMonthAndYear
2008-11-17
CY2008Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2008Q4 us-gaap Share Price
SharePrice
6.00
CY2008Q4 dvax Rights Expiration Date
RightsExpirationDate
2018-11-17
CY2013Q4 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
7957000
CY2013Q4 us-gaap Equity Issuance Per Share Amount
EquityIssuancePerShareAmount
1.075
CY2014Q4 dvax Warrant To Purchase Common Stock
WarrantToPurchaseCommonStock
1100000
CY2014Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
15.00
CY2014Q4 dvax Number Of Warrants Exercised During Period
NumberOfWarrantsExercisedDuringPeriod
11000
CY2013Q4 dvax Number Of Warrants Exercised During Period
NumberOfWarrantsExercisedDuringPeriod
25000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1576000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
582000
CY2014 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
5000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1820000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1820000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1040000
CY2013Q4 dvax Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Nonvested Weighted Average Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsNonvestedWeightedAveragePrice
31.66
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
16.75
CY2014 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
9.90
CY2014Q4 dvax Share Based Compensation Arrangement By Share Based Payment Award Options And Equity Instruments Other Than Options Nonvested Weighted Average Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsNonvestedWeightedAveragePrice
27.48
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
27.48
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
33.10
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y26D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y26D
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y7D
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
833000
CY2014Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
833000
CY2014Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
649000
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
100000
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
300000
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
2700000
CY2014 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
5600000
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
12100000
CY2012 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
9600000
CY2014 dvax Share Based Compensation Arrangement By Share Based Payment Award Options And Rsu Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRsuOutstandingNumber
76247
CY2014 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2013 us-gaap Defined Contribution Plan Number Of Employees Covered
DefinedContributionPlanNumberOfEmployeesCovered
5
CY2014Q4 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
400000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-91121000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-67004000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
399000
CY2014 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-90722000
CY2014 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2014 us-gaap Income Tax Reconciliation State And Local Income Taxes
IncomeTaxReconciliationStateAndLocalIncomeTaxes
1204000
CY2014 us-gaap Income Tax Reconciliation Tax Credits
IncomeTaxReconciliationTaxCredits
1484000
CY2014 dvax Income Tax Reconciliation Deferred Compensation Charges
IncomeTaxReconciliationDeferredCompensationCharges
2710000
CY2013 dvax Income Tax Reconciliation Deferred Compensation Charges
IncomeTaxReconciliationDeferredCompensationCharges
3072000
CY2014 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
28093000
CY2013 us-gaap Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
22354000
CY2014Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
217000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-20825000
CY2014Q4 us-gaap Net Income Loss
NetIncomeLoss
-22286000
CY2014Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-13840000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.53
CY2014Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.94
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.13
CY2014Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.85
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26283000
CY2014Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26286000
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
162000
CY2014Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
217000
CY2013Q4 us-gaap Deferred Tax Liabilities Property Plant And Equipment
DeferredTaxLiabilitiesPropertyPlantAndEquipment
162000
CY2014Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
217000
CY2013Q4 us-gaap Deferred Tax Liabilities
DeferredTaxLiabilities
162000
CY2014 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
27800000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
22500000
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26291000
CY2014Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
26298000
CY2013Q1 us-gaap Revenues
Revenues
2085000
CY2013Q2 us-gaap Revenues
Revenues
3392000
CY2013Q3 us-gaap Revenues
Revenues
2927000
CY2013Q4 us-gaap Revenues
Revenues
2847000
CY2014 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
295000
CY2013 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
-55000
CY2012 us-gaap Income Tax Reconciliation Other Adjustments
IncomeTaxReconciliationOtherAdjustments
771000
CY2014Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
178008000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
147655000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
22914000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
21336000
CY2014Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
9053000
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Reserves
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsReserves
9501000
CY2014Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
8601000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
10662000
CY2014Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
654000
CY2013Q4 us-gaap Deferred Tax Assets Deferred Income
DeferredTaxAssetsDeferredIncome
2486000
CY2014Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1531000
CY2013Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
1255000
CY2014Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
220761000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
192895000
CY2014Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
220544000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
192733000
CY2014Q4 us-gaap Deferred Taxes Business Combination Valuation Allowance Allocated To Contributed Capital
DeferredTaxesBusinessCombinationValuationAllowanceAllocatedToContributedCapital
300000
CY2014Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
2426000
CY2014Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
0
CY2014 us-gaap Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
2426000
CY2014 us-gaap Unrecognized Tax Benefits Interest On Income Taxes Expense
UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
0
CY2014 us-gaap Unrecognized Tax Benefits Income Tax Penalties Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesExpense
0
CY2014Q1 us-gaap Revenues
Revenues
3498000
CY2014Q2 us-gaap Revenues
Revenues
3048000
CY2014Q3 us-gaap Revenues
Revenues
2209000
CY2014Q4 us-gaap Revenues
Revenues
2277000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-17164000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-15675000
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
-13056000
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20825000
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-17164000
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15675000
CY2013Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21525000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.14
CY2013Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.94
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.86
CY2013Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.91
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18285000
CY2013Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18291000
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18302000
CY2013Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23588000

Files In Submission

Name View Source Status
0001564590-15-001348-index-headers.html Edgar Link pending
0001564590-15-001348-index.html Edgar Link pending
0001564590-15-001348.txt Edgar Link pending
0001564590-15-001348-xbrl.zip Edgar Link pending
dvax-10k_20141231.htm Edgar Link pending
dvax-20141231.xml Edgar Link completed
dvax-20141231.xsd Edgar Link pending
dvax-20141231_cal.xml Edgar Link unprocessable
dvax-20141231_def.xml Edgar Link unprocessable
dvax-20141231_lab.xml Edgar Link unprocessable
dvax-20141231_pre.xml Edgar Link unprocessable
dvax-ex1035_20141231134.htm Edgar Link pending
dvax-ex1036_20141231132.htm Edgar Link pending
dvax-ex1037_20141231133.htm Edgar Link pending
dvax-ex121_20141231131.htm Edgar Link pending
dvax-ex211_20141231125.htm Edgar Link pending
dvax-ex231_20141231126.htm Edgar Link pending
dvax-ex311_20141231127.htm Edgar Link pending
dvax-ex312_20141231128.htm Edgar Link pending
dvax-ex321_20141231129.htm Edgar Link pending
dvax-ex322_20141231130.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending